Davis L. Temple

1.3k total citations
32 papers, 969 citations indexed

About

Davis L. Temple is a scholar working on Organic Chemistry, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Davis L. Temple has authored 32 papers receiving a total of 969 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Organic Chemistry, 6 papers in Molecular Biology and 5 papers in Cellular and Molecular Neuroscience. Recurrent topics in Davis L. Temple's work include Synthesis and Reactions of Organic Compounds (7 papers), Synthesis and Biological Evaluation (5 papers) and Neuroscience and Neuropharmacology Research (4 papers). Davis L. Temple is often cited by papers focused on Synthesis and Reactions of Organic Compounds (7 papers), Synthesis and Biological Evaluation (5 papers) and Neuroscience and Neuropharmacology Research (4 papers). Davis L. Temple collaborates with scholars based in United States and Germany. Davis L. Temple's co-authors include Arlene S. Eison, A. I. MEYERS, Duncan P. Taylor, L.A. Riblet, Michael S. Eison, Edward D. Mihelich, Joseph P. Yevich, James S. New, R. L. Nolen and H.C. Stanton and has published in prestigious journals such as Journal of the American Chemical Society, SHILAP Revista de lepidopterología and The American Journal of Medicine.

In The Last Decade

Davis L. Temple

30 papers receiving 897 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Davis L. Temple United States 16 417 300 276 107 100 32 969
Michael S. Hadley United Kingdom 16 494 1.2× 277 0.9× 472 1.7× 90 0.8× 88 0.9× 55 1.0k
Elisabetta Maciocco Italy 20 204 0.5× 450 1.5× 244 0.9× 59 0.6× 55 0.6× 41 957
Mark W. Dudley United States 21 362 0.9× 365 1.2× 524 1.9× 133 1.2× 20 0.2× 38 1.3k
Nigel Austin United Kingdom 14 165 0.4× 253 0.8× 329 1.2× 62 0.6× 89 0.9× 24 727
L.A. Riblet United States 15 142 0.3× 709 2.4× 356 1.3× 161 1.5× 123 1.2× 22 1.1k
Ronald G. Browne United States 13 347 0.8× 503 1.7× 337 1.2× 114 1.1× 30 0.3× 23 1.3k
Deborah K. Hyslop United States 12 93 0.2× 515 1.7× 324 1.2× 142 1.3× 50 0.5× 19 900
Marshall B. Wallach United States 15 134 0.3× 269 0.9× 177 0.6× 176 1.6× 25 0.3× 27 697
Garrick P. Smith Denmark 15 153 0.4× 282 0.9× 326 1.2× 232 2.2× 77 0.8× 23 865
Harry Howard United States 11 469 1.1× 250 0.8× 319 1.2× 106 1.0× 27 0.3× 27 1.2k

Countries citing papers authored by Davis L. Temple

Since Specialization
Citations

This map shows the geographic impact of Davis L. Temple's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Davis L. Temple with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Davis L. Temple more than expected).

Fields of papers citing papers by Davis L. Temple

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Davis L. Temple. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Davis L. Temple. The network helps show where Davis L. Temple may publish in the future.

Co-authorship network of co-authors of Davis L. Temple

This figure shows the co-authorship network connecting the top 25 collaborators of Davis L. Temple. A scholar is included among the top collaborators of Davis L. Temple based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Davis L. Temple. Davis L. Temple is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cohen, Adam B., Davis L. Temple, Christopher Webb, et al.. (2024). Renal transplant nephrolithiasis: Presentation, management and follow‐up with control comparisons. SHILAP Revista de lepidopterología. 5(10). 1048–1055. 1 indexed citations
3.
Cohen, Adam B., Davis L. Temple, Christopher Webb, et al.. (2024). Bladder Stones in Renal Transplant Patients: Presentation, Management, and Follow-up. Urologia Internationalis. 108(5). 399–405. 1 indexed citations
4.
5.
Yevich, Joseph P., James S. New, Duncan P. Taylor, et al.. (1992). Synthesis and biological characterization of .alpha.-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogs as potential atypical antipsychotic agents. Journal of Medicinal Chemistry. 35(24). 4516–4525. 26 indexed citations
6.
Yevich, Joseph P., Arlene S. Eison, Frank D. Yocca, et al.. (1990). Gepirone hydrochloride: preclinical pharmacology and recent clinical findings.. PubMed. 361. 443–51. 1 indexed citations
7.
New, James S., Joseph P. Yevich, Davis L. Temple, et al.. (1988). Atypical antipsychotic agents: patterns of activity in a series of 3-substituted 2-pyridinyl-1-piperazine derivatives. Journal of Medicinal Chemistry. 31(3). 618–624. 17 indexed citations
8.
Gomoll, Allen W. & Davis L. Temple. (1987). Mechanism of acute vasodepressor responses elicited by tiprinast and disodium cromoglycate following intravenous injection in anesthetized dogs. Drug Development Research. 10(2). 57–62. 6 indexed citations
9.
New, James S., Joseph P. Yevich, Michael S. Eison, et al.. (1986). Buspirone analogs. 2. Structure-activity relationships of aromatic imide derivatives. Journal of Medicinal Chemistry. 29(8). 1476–1482. 21 indexed citations
10.
Hammerstad, John P., Julie Carter, John G. Nutt, et al.. (1986). Buspirone in Parkinsonʼs Disease. Clinical Neuropharmacology. 9(6). 556–560. 28 indexed citations
11.
New, James S., et al.. (1983). Preparation of specifically‐labelled buspirone ‐14C and buspirone ‐ 15N2. Journal of Labelled Compounds and Radiopharmaceuticals. 20(10). 1207–1211. 6 indexed citations
12.
Yevich, Joseph P., et al.. (1982). Antiallergics: 3-(1H-tetrazol-5-yl)-4H-pyrimido[2,1-b]benzothiazol-4-ones. Journal of Medicinal Chemistry. 25(7). 864–868. 29 indexed citations
13.
Temple, Davis L., Joseph P. Yevich, John D. Catt, et al.. (1980). Substituted 6,7-dihydroimidazo[1,2-a]purin-9(4H)-ones. Journal of Medicinal Chemistry. 23(11). 1188–1198. 13 indexed citations
14.
Temple, Davis L.. (1980). Drugs affecting the respiratory system : based on a symposium sponsored by the Division of Medicinal Chemistry, at the 175th meeting of the American Chemical Society, Anaheim, California, March 13-16, 1978. Medical Entomology and Zoology. 1 indexed citations
15.
MEYERS, A. I., et al.. (1974). Oxazolines. XI. Synthesis of functionalized aromatic and aliphatic acids. Useful protecting group for carboxylic acids against Grignard and hydride reagents. The Journal of Organic Chemistry. 39(18). 2787–2793. 119 indexed citations
16.
Comer, William T. & Davis L. Temple. (1973). Reaction of cyclopentanones with methylsulfinyl carbanion. The Journal of Organic Chemistry. 38(12). 2121–2125. 5 indexed citations
17.
MEYERS, A. I. & Davis L. Temple. (1970). Syntheses via 2-oxazolines. III. Formation of substituted benzoic acids or esters utilizing the Grignard reagent of 2-(bromophenyl)-2-oxazolines. Journal of the American Chemical Society. 92(22). 6646–6647. 20 indexed citations
18.
Temple, Davis L. & Joseph Sam. (1970). 1‐Arylquinolizidines. Journal of Heterocyclic Chemistry. 7(4). 847–855. 5 indexed citations
19.
Sam, Joseph, et al.. (1969). Epimeric 2-hydroxy-2-phenylquinolizidines. Journal of Medicinal Chemistry. 12(1). 144–146. 5 indexed citations
20.
Temple, Davis L. & Joseph Sam. (1968). Stereochemistry of epimeric 1‐hydroxy‐N‐methylquinolizidinium iodides. Journal of Heterocyclic Chemistry. 5(4). 441–448. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael S. Hadley Breakdown of academic impact, for papers by Elisabetta Maciocco Breakdown of academic impact, for papers by Mark W. Dudley Breakdown of academic impact, for papers by Nigel Austin Breakdown of academic impact, for papers by L.A. Riblet Breakdown of academic impact, for papers by Ronald G. Browne Breakdown of academic impact, for papers by Deborah K. Hyslop Breakdown of academic impact, for papers by Marshall B. Wallach Breakdown of academic impact, for papers by Garrick P. Smith Breakdown of academic impact, for papers by Harry Howard
Rankless by CCL
2026